Skip to content

The impact of adjuvant chemoradiation on pancreatic endocinal and exocinal founctions in gastric cancer

The impact of adjuvant chemoradiation on pancreatic endocinal and exocinal founctions in gastric cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017131
Enrollment
Unknown
Registered
2018-07-13
Start date
2018-07-01
Completion date
Unknown
Last updated
2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

All patients:Blood sampling

Sponsors

Fudan University Huadong Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Aged = 18 years; 2) Performance status ECOG 0-2; 3) All patients must have microscopically confirmed adenocarcinoma of the stomach; 4) All patients must have undergone a potentially curative resection of a primary gastric tumor (R0 resection); Patients with tumor stages IB through IIIC are eligible for this study. Radiation therapy must begin within 8 weeks of surgery; 5) Patients may not have received prior radiation therapy to the treatment field; 6) Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.

Exclusion criteria

Exclusion criteria: 1) Any metastatic disease (M1); 2) Patients who are unable to tolerate treatment are excluded, such as severe cardiopulmonary insufficiency, severe arrhythmia, myocardial infarction, angina pectoris, severe coagulant disease, severe liver disease and so on; 3) Patients had T4 disease due to the direct involvement of pancreas, or patients had undergone pancreatic tissue resection; 4) Pregnant or nursing female participants; 5) Unwilling or unable to follow protocol requirements.

Design outcomes

Primary

MeasureTime frame
insulin;C-peptide;glycated albumin;glycosylated hemoglobin;amylase;lipase;

Secondary

MeasureTime frame
overallsurvival;Progression-Free-Survival;Quality of Life;

Countries

China

Contacts

Public ContactXiangpeng Zheng

Fudan University Huadong Hospital

zhengxp@fudan.edu.cn+86 18601764699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026